CRL for subcutaneous Rybrevant due to issues with manufacturing. Another setback for $JNJ in their bid to capture some of the first-line EGFR mutant lung cancer www.biospace.com/fda/j-js-fda... - ThreadSky | a Reddit-style client for Bluesky

jordixiol.bsky.social • 76 days ago

CRL for subcutaneous Rybrevant due to issues with manufacturing. Another setback for $JNJ in their bid to capture some of the first-line EGFR mutant lung cancer

https://www.biospace.com/fda/j-js-fda-bid-for-subcutaneous-rybrevant-falls-short

Comments